Literature DB >> 16986008

Radiation therapy failure in prostate cancer patients: risk factors and methods of detection.

Michael K Brawer.   

Abstract

Radiation therapy for clinically localized prostatic carcinoma remains one of the mainstays among therapeutic approaches; however, patients continue to fail radiation therapy at too high a rate. This article reviews the risk factors and methods of detection for prostate cancer recurrence. The relative merits of the three major pre-therapy prognostic indicators-TNM staging, Gleason score, and serum prostate-specific antigen (PSA) levels-are discussed. The use of staging and Gleason score, as well as digital rectal examination, transrectal ultrasound, and post-radiation prostate biopsies in detecting failure of radiation therapy is reviewed. Challenges relating to the use of serum PSA levels as an indicator of recurrence are examined. Finally, this article makes recommendations as to procedure for evaluating patients suspected of failing radiation therapy.

Entities:  

Year:  2002        PMID: 16986008      PMCID: PMC1477545     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  61 in total

1.  Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel.

Authors: 
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-03-15       Impact factor: 7.038

2.  Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen.

Authors:  J M Crook; Y A Bahadur; R G Bociek; G A Perry; S J Robertson; B A Esche
Journal:  Cancer       Date:  1997-01-15       Impact factor: 6.860

3.  Preliminary observations on the results of combined temporary 192iridium implantation and external beam irradiation for carcinoma of the prostate.

Authors:  P C Bosch; K A Forbes; S Prassvinichai; J B Miller; H Golji; D C Martin
Journal:  J Urol       Date:  1986-04       Impact factor: 7.450

4.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.

Authors:  A W Partin; M W Kattan; E N Subong; P C Walsh; K J Wojno; J E Oesterling; P T Scardino; J D Pearson
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

5.  External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.

Authors:  P Kupelian; J Katcher; H Levin; C Zippe; J Suh; R Macklis; E Klein
Journal:  Cancer J Sci Am       Date:  1997 Mar-Apr

6.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

Authors:  A W Partin; J Yoo; H B Carter; J D Pearson; D W Chan; J I Epstein; P C Walsh
Journal:  J Urol       Date:  1993-07       Impact factor: 7.450

7.  Carcinoma of the prostate: results of post-irradiation biopsy.

Authors:  F S Freiha; M A Bagshaw
Journal:  Prostate       Date:  1984       Impact factor: 4.104

8.  The effect of pelvic radiation therapy on serum levels of prostate specific antigen.

Authors:  C G Willett; A L Zietman; W U Shipley; J J Coen
Journal:  J Urol       Date:  1994-06       Impact factor: 7.450

9.  Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation.

Authors:  F A Critz; R S Tarlton; D A Holladay
Journal:  Cancer       Date:  1995-05-01       Impact factor: 6.860

10.  Prostate-specific antigen and radiation therapy for clinically localized prostate cancer.

Authors:  G K Zagars; A Pollack; V S Kavadi; A C von Eschenbach
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-05-15       Impact factor: 7.038

View more
  11 in total

1.  Diffusion-weighted MRI in early assessment of tumour response to radiotherapy in high-risk prostate cancer.

Authors:  L Liu; N Wu; H Ouyang; J-R Dai; W-H Wang
Journal:  Br J Radiol       Date:  2014-08-27       Impact factor: 3.039

2.  Adjuvant Effect of IV Clodronate on the Delay of Bone Metastasis in High-Risk Prostate Cancer Patients: A Prospective Study.

Authors:  Paulo Rodrigues; Flavio O Hering; Alex Meller
Journal:  Cancer Res Treat       Date:  2011-12-27       Impact factor: 4.679

3.  Selecting treatment for high-risk, localized prostate cancer: the case for radiation therapy.

Authors:  Robert Meier; Michael K Brawer
Journal:  Rev Urol       Date:  2002

Review 4.  Advances in imaging and in non-surgical salvage treatments after radiorecurrence in prostate cancer: what does the oncologist, radiotherapist and radiologist need to know?

Authors:  Giovanni Luca Gravina; Vincenzo Tombolini; Mario Di Staso; Pietro Franzese; Pierluigi Bonfili; Antonio Gennarelli; Leda Di Nicola; Carlo Masciocchi; Ernesto Di Cesare
Journal:  Eur Radiol       Date:  2012-07-14       Impact factor: 5.315

Review 5.  Management of patients with biochemical recurrence after local therapy for prostate cancer.

Authors:  Channing J Paller; Emmanuel S Antonarakis; Mario A Eisenberger; Michael A Carducci
Journal:  Hematol Oncol Clin North Am       Date:  2013-09-18       Impact factor: 3.722

6.  The impact of positron emission tomography on primary tumour delineation and dosimetric outcome in intensity modulated radiotherapy of early T-stage nasopharyngeal carcinoma.

Authors:  Vincent W C Wu; Wan-Shun Leung; Kwun-Lam Wong; Ying-Kit Chan; Wing-Lam Law; Wing-Kwan Leung; Yat-Long Yu
Journal:  Radiat Oncol       Date:  2016-08-24       Impact factor: 3.481

7.  Quantitative transrectal shear wave elastography undergoing salvage extraperitoneal laparoscopic radical prostatectomy following failed radiotherapy.

Authors:  Cheng Wei; Magdalena Szewczyk-Bieda; Paddy Nibblok; E Brown; Stephen Lang; Ghulam Nabi
Journal:  Surg Endosc       Date:  2018-05-14       Impact factor: 4.584

Review 8.  MRI in prostate cancer.

Authors:  Mahyar Ghafoori; Manijeh Alavi; Mounes Aliyari Ghasabeh
Journal:  Iran Red Crescent Med J       Date:  2013-12-05       Impact factor: 0.611

9.  HDAC inhibitor confers radiosensitivity to prostate stem-like cells.

Authors:  F M Frame; D Pellacani; A T Collins; M S Simms; V M Mann; G D D Jones; M Meuth; R G Bristow; N J Maitland
Journal:  Br J Cancer       Date:  2013-11-12       Impact factor: 7.640

10.  Mechanisms of growth inhibition of primary prostate epithelial cells following gamma irradiation or photodynamic therapy include senescence, necrosis, and autophagy, but not apoptosis.

Authors:  Fiona M Frame; Huguette Savoie; Francesca Bryden; Francesca Giuntini; Vincent M Mann; Matthew S Simms; Ross W Boyle; Norman J Maitland
Journal:  Cancer Med       Date:  2015-11-21       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.